KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Receivables (2020 - 2022)

Vir Biotechnology's Receivables history spans 3 years, with the latest figure at $7.0 million for Q2 2022.

  • On a quarterly basis, Receivables changed N/A to $7.0 million in Q2 2022 year-over-year; TTM through Jun 2022 was $7.0 million, a N/A change, with the full-year FY2021 number at $773.1 million, changed N/A from a year prior.
  • Receivables hit $7.0 million in Q2 2022 for Vir Biotechnology, down from $1.2 billion in the prior quarter.
  • Over the last five years, Receivables for VIR hit a ceiling of $1.2 billion in Q1 2022 and a floor of $3.8 million in Q2 2020.
  • Historically, Receivables has averaged $387.5 million across 3 years, with a median of $159.0 million in 2021.
  • The widest YoY moves for Receivables: up 443.63% in 2022, down 443.63% in 2022.
  • Tracing VIR's Receivables over 3 years: stood at $3.8 million in 2020, then soared by 20244.18% to $773.1 million in 2021, then crashed by 99.09% to $7.0 million in 2022.
  • Business Quant data shows Receivables for VIR at $7.0 million in Q2 2022, $1.2 billion in Q1 2022, and $773.1 million in Q4 2021.